Navigation Links
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
Date:7/27/2009

COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy when compared to placebo. In this study, uterine bleeding was not statistically different from placebo and the rate of endometrial hyperplasia in doses being considered for therapeutic use was <1%. BZA/CE is being studied by Wyeth Pharmaceuticals for the treatment of moderate-to-severe menopausal vasomotor symptoms such as hot flushes, night sweats and vulvar and vaginal atrophy, and for the prevention of postmenopausal osteoporosis.

The data, published online July 27, 2009 in the peer-reviewed journal Fertility and Sterility, is from the Selective estrogens Menopause And Response to Therapy (SMART-1) clinical trial. SMART-1 was designed to explore the hypothesis that bazedoxifene, when paired with conjugated estrogens, may have the potential to eliminate the need for progestin in menopausal therapy in women with an intact uterus. BZA/CE is characterized by Wyeth as a TSEC (tissue selective estrogen complex) as it combines a selective estrogen receptor modulator (SERM) with conjugated estrogens.

Across the SMART-1 trial, the incidence of treatment-emergent adverse events, breast pain, serious adverse events and withdrawals due to adverse events were similar among the active treatment groups and placebo.

About SMART-1

SMART-1 was a two-year, multinational, multicenter, randomized, double-blind, placebo- and active-control
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
9. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
10. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Accelerated orthodontic treatment will be a ... 2015 Annual Session, May 15-19, as seven of ... AcceleDent ® . Manufactured by OrthoAccel ® ... is a FDA-cleared, Class II medical device that ... 50 percent with just 20 minutes of daily ...
(Date:3/31/2015)... 2015 Ryan & Maniskas, LLP ... of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company") (NASDAQ: ... and other violations of law related to the Company,s ... in a transaction valued at approximately $1.1 billion. ... like to learn more about this class action or ...
(Date:3/31/2015)... 2015 Medela has announced the addition ... ® Motion™-Endure personal pumps to its Negative Pressure ... These new devices, along with the Invia ® ... provide innovative, high-quality NPWT solutions, designed to provide ... "We are happy to be able ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. 2Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2
... BEIJING , July 7 ... "Company"), a growing developer,manufacturer and seller of medicine and drugs in ... will present at the Global Hunter,Securities 2010 China Conference held ... are noted below. , , Date: ...
... BEIJING , July 7 /PRNewswire-Asia-FirstCall/ -- ... CCM ), operator of,the largest network of radiotherapy ... it has filed its annual report for the fiscal year ... U.S. Securities and Exchange,Commission on June 30, 2010 . ...
Cached Medicine Technology:Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference 2Concord Medical Files 2009 Annual Report on Form 20-F 2
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By product ... Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), End ... studies the major market drivers, restraints, opportunities and ... Rest of the world (RoW). , The ... $3.58 billion by 2019 from $2.4 billion in ...
(Date:3/31/2015)... Safeware has been recognized ... Central Ohio, an awards program presented by Columbus Business ... the awards program, held on March 10, 2015. These ... health, with outstanding health and wellness initiatives. , ... a healthy environment for their associates. Business Frist, OhioHealth ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... A' Design Award and Competition is pleased ... Daniel Dion has been announced as a winner of ... Devices and Research Equipment Design Competition Category. ... behind the award winning Medical Product design Bruker EVOQ ... direction of Dr. Rohan Thakur and the Bruker team ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today that third ... third quarter 2006 revenue of $23.4,million. Revenue from Osteotech,s ... for the three months ended September 30,2007 as compared ... for the,third quarter of 2006. Gross margin improved to ...
... 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... Cameron Groome, Executive,Vice-President, Corporate & Strategic Development, will ... Healthcare Conference in New York City,tomorrow. Mr. Groome ... the Holmes,II Room of the New York Palace ...
... by web cast-, TORONTO, Nov. 6 /PRNewswire-FirstCall/ ... in the research,development and commercialization of pharmaceutical products ... that on,Wednesday, November 7, 2007, at 10:30 a.m. ... and CEO will present a corporate overview of ...
... Elite Books, TUCSON, Ariz., Nov. 5 We all ... the development of Alzheimer,s Disease and heart,disease, along with a ... In her seminal book, The Apo E Gene Diet: ... Body,s Own Genes,(Elite, Hardcover, $27.95, November 1, 2007), Pamela McDonald, ...
... 5 StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: ... Administration ("FDA"), through its Center for Devices and,Radiological ... Laboratory,Improvements Amendments of 1988 ("CLIA") for an HIV ... The HIV 1/2 product,is marketed and distributed worldwide ...
... offices could ... YORK, Nov. 5 Group Health Incorporated (GHI) and,HIP ... educational seminar in,New York City on November 6 for ... be held at HIP,headquarters, 55 Water St., will provide ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference 2Health News:Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3Health News:GHI and HIP Lead Effort to Expand Electronic Health Record System Throughout the City of New York 2
... molecular labs a more advanced alternative for ... MGB technology, combined with post-PCR dissociation melt ... provide molecular labs more powerful tools for ... or genetic mutations associated with disease, as ...
... ASRs* are specifically designed for PCR ... two-color fluorescence detection systems. The NGEN ... detection of mutations associated with cystic ... well as reagents for the detection ...
... MGB Alert Detection Reagents provide molecular ... PCR based assays. By using our MGB ... analysis, Nanogen is now able to provide ... nucleic acid sequences of specific organisms or ...
... NGEN-brand ASRs* are specifically designed for ... with two-color fluorescence detection systems. The ... the detection of mutations associated with ... as well as reagents for the ...
Medicine Products: